MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Sees Large Increase in Short Interest

Key Points

• MAIA Biotechnology, Inc. experienced a significant increase in short interest of 75.3% in July, with total short interest reaching 713,100 shares.
• Director Stan Smith acquired 33,333 shares of MAIA stock, increasing his ownership by 2.62% and bringing his total holdings to over 1.3 million shares.
• Large institutional investors have been active, with notable acquisitions including Geode Capital Management increasing its stake by 3.6% and Centric Wealth Management growing its position by a dramatic 740.2%.

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - ) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 713,100 shares, agrowthof75.3% from the July 15th total of 406,900 shares. Based on an average trading volume of 398,900 shares, the short-interest ratio is presently 1.8 days. Approximately3.3% of the shares of the company are short sold. Approximately3.3% of the shares of the company are short sold. Based on an average trading volume of 398,900 shares, the short-interest ratio is presently 1.8 days.

Insider Activity

In related news, Director Stan Smith purchased 33,333 shares of MAIA Biotechnology stock in a transaction dated Tuesday, June 3rd. The stock was bought at an average cost of $1.50 per share, for a total transaction of $49,999.50. Following the completion of the transaction, the director owned 1,305,059 shares in the company, valued at $1,957,588.50. This trade represents a 2.62% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 32.32% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Centerpoint Advisory Group purchased a new stake in MAIA Biotechnology during the 2nd quarter valued at about $28,000. Marshall Wace LLP purchased a new position in MAIA Biotechnology during the second quarter valued at $29,000. Jane Street Group LLC purchased a new stake in MAIA Biotechnology during the 2nd quarter valued at $52,000. Geode Capital Management LLC increased its position in MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock valued at $400,000 after acquiring an additional 7,746 shares during the last quarter. Finally, Centric Wealth Management grew its stake in shares of MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company's stock valued at $1,032,000 after acquiring an additional 505,150 shares during the period. 5.65% of the stock is owned by hedge funds and other institutional investors.

MAIA Biotechnology Stock Performance

MAIA traded down $0.08 on Tuesday, reaching $1.50. The company had a trading volume of 126,626 shares, compared to its average volume of 392,661. MAIA Biotechnology has a 52-week low of $1.40 and a 52-week high of $3.7420. The company has a market cap of $49.49 million, a price-to-earnings ratio of -2.63 and a beta of 0.01. The business has a 50 day simple moving average of $1.71 and a 200 day simple moving average of $1.78.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.